TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00647218

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy with concurrent Paclitaxel
Description: Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal Therapy
Description: After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
Study: NCT00920907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
Study: NCT02060448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion awareness training
Description: Four weekly individual treatment sessions focused on increasing awareness of one's emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion awareness training
Description: Four weekly individual treatment sessions focused on increasing awareness of one's emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion awareness training
Description: Four weekly individual treatment sessions focused on increasing awareness of one's emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion awareness training
Description: Four weekly individual treatment sessions focused on increasing awareness of one's emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Description: Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Description: Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
Study: NCT04652492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab in combination with cTACE
Description: On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
Study: NCT02574312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE TKA with ATTUNE RUI
Description: ATTUNE TKA with ATTUNE RUI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE TKA with ATTUNE SUI
Description: ATTUNE TKA with ATTUNE SUI
Study: NCT01276015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
Study: NCT02060448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Description: Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Description: Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
Study: NCT01852357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Neurofeedback
Description: Feedback generated by data not associated with the current participant.
Study: NCT04308369

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood collection arm
Description: Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
Study: NCT00558376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate
Description: Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
Study: NCT03906227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENUMERATION OF CD5+ B Cells
Description: A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENUMERATION OF CD5+ B Cells
Description: A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENUMERATION OF CD5+ B Cells
Description: A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
Study: NCT03751774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAMAACT
Description: Post graduate training and health education materials
Study: NCT02379845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBTXR3
Description: One intratumor implantation by injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 5 weeks/50 Gy (5 x 2 Gy by week)
Study: NCT02136394

Intervention type: OTHER
Intervention: Gastro-esophageal reflux
Description: This is an observational study. The exposure is the gastro-esophageal reflux.
Study: NCT03158545

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil Placebo
Description: olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-rich
Description: EPA-rich omega-3 oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich
Description: DHA-rich omega-3 oil
Study: NCT00974077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control
Description: Patients receive MBCT with a delay of 6 months.
Study: NCT00842517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Study: NCT04083742

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat angle measurements performed on each of the 3 Anterion devices and the 3 reference devices

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat angle measurements performed on each of the 3 Anterion devices and the 3 reference devices
Study: NCT00339079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
Study: NCT05214677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809
Description: pelubiprofen 30mg
Study: NCT02694055

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Removal of point-of-care user fees
Description: User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infrastructure improvements at primary health centre
Description: Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infrastructure improvements at primary health centre
Description: Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of primary health centre staff
Description: Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training of primary health centre staff
Description: Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management
Study: NCT03401580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viena II 160/10
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viena II 190/10
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viena II 160/12
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viena II 190/12
Description: once daily
Study: NCT03059888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Subcutaneous administration of abatacept
Study: NCT04179656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg administered orally, once daily, continuously in 21 day cycles
Study: NCT05214677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-1
Description: pelubiprofen 30mg (PELUBI tab.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-1
Description: pelubiprofen 30mg (PELUBI tab.)
Study: NCT03102528

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03615326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg on Day 1 of each 3-week cycle as an IV infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Solution for IV infusion on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
Study: NCT02379845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: 5 weeks/50 Gy (5 x 2 Gy by week)
Study: NCT03901703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and Rehabilitation
Description: The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and Rehabilitation
Description: The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and Rehabilitation
Description: The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
Study: NCT00006487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirapazamine
Description: During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion.
Study: NCT00339079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Therapy
Description: The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Therapy
Description: The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
Study: NCT00881569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: CS-7017 administered orally, twice daily continuously for 6 weeks
Study: NCT00867763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In vitro maturation and in vitro fertilization
Description: No gonadotropin, eggs harvested early

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low doses of gonadotropin stimulation.
Description: Gonadotropin followed by conventional IVF
Study: NCT00006487

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
Study: NCT02469038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath catheter
Description: Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
Study: NCT02050971

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Infusion
Description: Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Intravenous Infusion of Peripheral Blood or its Components
Description: Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
Study: NCT01555957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous lipid
Description: intravenous given daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous lipid
Description: intravenous given daily for 6 weeks
Study: NCT02809261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perineural injection with 5% dextrose
Description: Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
Study: NCT00339079

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
Study: NCT00541359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01142323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: 160 mg po daily
Study: NCT04076072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Utravit High-Speed 10000 cpm Beveled Probe
Description: This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm
Description: This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
Study: NCT04606511

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Circumference tape measurements
Description: centimeter and volume criterias

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Circumference tape measurements
Description: centimeter and volume criterias

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Indocyanine green lymphangiography
Description: Presence of dermal backflow

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Indocyanine green lymphangiography
Description: Presence of dermal backflow

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: bioimpedance spectroscopy
Description: 7.5 and 10 L-DEX criterias

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: bioimpedance spectroscopy
Description: 7.5 and 10 L-DEX criterias
Study: NCT02809261

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided perineural injection with normal saline
Description: Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline is safe for perineural injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Dextrose
Description: 5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
Study: NCT04606511

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Symptom score
Description: using lymph-icf, DASH and SF-36 questionnaires
Study: NCT03615326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
Study: NCT00911664

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Weekly dose of 5600 IU (800 IU per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No supplementation
Description: Control

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Weekly dose of 11,200 IU (1600 IU per day)
Study: NCT01032785

Intervention type: DEVICE
Intervention: no interventions
Description: no interventions
Study: NCT03969433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMSi Porti
Description: Data collections
Study: NCT01872676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spine manipulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manipulation sham
Study: NCT02408653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Study: NCT03969433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bloomlife sensor
Description: Data collections
Study: NCT00259805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 given as an IV infusion once weekly for four doses